The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
13:17
The European Union introduces new rules for the design, production, and treatment of end-of-life vehicles, starting from August 13.
13:16
The British economy grew by 0.4% in the second quarter, providing a moment of respite for the new Prime Minister Andy Burnham.
13:14
The Commission is preparing new measures for victims of digital crime, children, and vulnerable individuals.
13:08
Mugur Isărescu states that Romania does not meet the necessary criteria for adopting the euro: "The country is not ready"
13:01
The BNR has revised the inflation forecast for the end of 2026 to 6.1% and estimates an inflation of 3.4% at the end of 2027.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
